Data from the phase II NP30179 expansion study demonstrated that, after a median follow-up of more than 12 months, fixed-duration glofitamab—an investigational CD20xCD3 T cell-engaging bispecific antibody—induced durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma who had received a median of three prior therapies.
Researchers with Memorial Sloan Kettering and City of Hope have created a tool that uses machine learning to assess a non-Hodgkin lymphoma patient’s likely response to chimeric antigen receptor T-cell therapy before starting the treatment, according to study results published on April 1 in Nature Medicine.
